
Dominic P Francese

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6463781/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. Journal of the American College of Cardiology, 2020, 75, 2950-2973.	1.2	2,392
2	Incidence, Predictors, and Impact ofÂPost-Discharge Bleeding After Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2015, 66, 1036-1045.	1.2	344
3	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. Thrombosis and Haemostasis, 2020, 120, 1004-1024.	1.8	206
4	A Randomized Trial of a DedicatedÂBifurcation Stent Versus Provisional Stenting in the Treatment of Coronary Bifurcation Lesions. Journal of the American College of Cardiology, 2015, 65, 533-543.	1.2	101
5	Mortality, Length of Stay, and Cost Implications of Procedural Bleeding After Percutaneous Interventions Using Large-Bore Catheters. JAMA Cardiology, 2017, 2, 798.	3.0	84
6	Two-year outcomes after percutaneous coronary intervention of calcified lesions with drug-eluting stents. International Journal of Cardiology, 2017, 231, 61-67.	0.8	71
7	Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. American Journal of Cardiology, 2016, 117, 1877-1883.	0.7	34
8	Imaging and Functional Testing to Assess Clinical and Subclinical Neurological Events After Transcatheter or Surgical Aortic Valve Replacement. Journal of the American College of Cardiology, 2014, 64, 1950-1963.	1.2	30
9	Reasonable incomplete revascularisation after percutaneous coronary intervention: the SYNTAX Revascularisation Index. EuroIntervention, 2015, 11, 634-642.	1.4	30
10	Dedicated Bifurcation Stent for the Treatment of Bifurcation Lesions InvolvingÂLarge Side Branches. JACC: Cardiovascular Interventions, 2016, 9, 1338-1346.	1.1	22
11	Outcomes of a dedicated stent in coronary bifurcations with large side branches: A subanalysis of the randomized <scp>TRYTON</scp> bifurcation study. Catheterization and Cardiovascular Interventions, 2016, 87, 1231-1241.	0.7	20
12	Relation Between Platelet Count and Platelet Reactivity to Thrombotic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. American Journal of Cardiology, 2016, 117, 1703-1713.	0.7	18
13	Angiographic predictors of 2â€year stent thrombosis in patients receiving drugâ€eluting stents: Insights from the <scp>ADAPTâ€DES</scp> study. Catheterization and Cardiovascular Interventions, 2017, 89, 26-35.	0.7	16
14	Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin versus Heparin in Acute Myocardial Infarction: Rationale and Methodology. Thrombosis and Haemostasis, 2020, 120, 348-362.	1.8	13
15	Sulodexide versus Control and the Risk of Thrombotic and Hemorrhagic Events: Meta-Analysis of Randomized Trials. Seminars in Thrombosis and Hemostasis, 2020, 46, 908-918.	1.5	13
16	Risk stratification of patients undergoing medical therapy after coronary angiography. European Heart Journal, 2016, 37, 3103-3110.	1.0	12
17	Safety and Efficacy of Bivalirudin in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: From the REPLACE-2, ACUITY and HORIZONS-AMI Trials. American Journal of Cardiology, 2016, 118, 6-16.	0.7	9
18	Clinical profile and impact of family history of premature coronary artery disease on clinical outcomes of patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: analysis from the HORIZONS-AMI Trial. Cardiovascular Revascularization Medicine, 2014, 15, 375-380.	0.3	8

#	Article	IF	CITATIONS
19	Antiplatelet strategies in acute coronary syndromes: design and methodology of an international collaborative network meta-analysis of randomized controlled trials. Minerva Cardiology and Angiology, 2021, 69, 398-407.	0.4	2
20	How Cox models react to a study-specific confounder in a patient-level pooled dataset: random effects better cope with an imbalanced covariate across trials unless baseline hazards differ. Journal of Applied Statistics, 2019, 46, 1903-1916.	0.6	1